Evidence map›Paper›PMID 34323039›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2021

[Co-delivery of Pirarubicin and Vinorelbine by Micelles for the Treatment of Breast Cancer].

Dan Chen, Hong-Li Zhou, Ting Zhao, Chen-Qi Guo, Rong-Ping Zhang, Jia Li, Tao Gong

Open access · greenAbstract read
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. [Expressions of miR-27a-3p mRNA andSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Dan ChenKey Laboratory of Drug Targeting and Delivery System of the Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Hong-Li ZhouKey Laboratory of Drug Targeting and Delivery System of the Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Ting ZhaoKey Laboratory of Drug Targeting and Delivery System of the Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Chen-Qi GuoKey Laboratory of Drug Targeting and Delivery System of the Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Rong-Ping ZhangKey Laboratory of Drug Targeting and Delivery System of the Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Jia LiWest China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Tao GongKey Laboratory of Drug Targeting and Delivery System of the Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo develop a pirarubicin (THP) and vinorelbine (VRL) codelivery nano-micellar system (T+V-CS micelles) of pirarubicin (THP) and vinorelbine (VRL) by using chondroitin sulfate-cholesterol polymers (CS-Chol) and DSPE-mPEG

methodsT+V-CS micelles were prepared by ultrasonic-dialysis method, and the physicochemical characterization were evaluated using multiple technological means. The anti-tumor efficacy of T+V-CS micelles

resultsT+V-CS micelles displayed a nearly spherical shape when observed through transmission electron microscope. The particle size and polydispersity indexes (PDI) of T+V-CS micelles was (155.5±4.5) nm and 0.170±0.003 respectively, while the Zeta potential was (-23.0±0.9) mV. Meanwhile, T+V-CS micelles demonstrated high encapsulation efficiency of (81.87±2.56)% for THP and (87.54±2.82)% for VRL and a high overall drug loading efficiency of (10.20±1.20)%.

conclusionThe study showed that T+V-CS micelles had excellent anti-tumor effect, offering a reference to the clinical treatment of breast cancer.

Indexed as

Antineoplastic AgentsBreast NeoplasmsAnimalsCell Line, TumorDoxorubicinDrug CarriersFemaleHumansMiceMice, Inbred BALB CMicellesPolyethylene GlycolsVinorelbineAntineoplastic AgentsDoxorubicinDrug CarriersMicellespirarubicinPolyethylene GlycolsVinorelbineBreast cancerMicellesPharmacodynamicsPirarubicinVinorelbine

Identifiers

PMID34323039
PMCPMC10409388
OpenAlexW3185189597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.